TRYPTO Therapeutics

Biotechnology Research • Berlin, Berlin, Germany • 1-10 Employees

Company overview

Headquarters	Robert-Rössle-Str. 10, Berlin, 13125, DE
Website	tryptotherapeutics.com
NAICS	541714
Employees	1-10

Key Contact at TRYPTO Therapeutics

Dirk Pleimes

Co-Founder

About TRYPTO Therapeutics

TRYPTO Therapeutics develops a novel class of Tryptophan Hydroxylase inhibitors for serotonin-dependent diseases. The overproduction of peripheral serotonin, catalyzed by the enzyme Tryptophan Hydroxylase 1, leads to the aggravation of many chronic and life-threatening diseases, such as Pulmonary Arterial Hypertension (PAH), Carcinoid Syndrome (CS), colorectal cancer (CRC) and obesity. We have developed and patented a novel class of TPH inhibitors (TPHi) with nanomolar potency in vitro to reduce the pathologically high serotonin synthesis in the periphery. Our new generation of TPHi differs in the scaffold, binding mode, and potency from the two TPHi currently on the market or under clinical investigation.

TRYPTO Therapeutics revenue & valuation

Annual revenue	$85,555
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$273,776
Total funding	No funding

Employees by Management Level

Total employees: 1-10

Seniority

Employees

Founder/Owner

Employees by Department

TRYPTO Therapeutics has 1 employees across 1 departments.

Departments

Number of employees

Funding Data

TRYPTO Therapeutics has never raised funding before.